ArticleUrologic oncology2017
Current beliefs and practice patterns among urologists regarding prostate magnetic resonance imaging and magnetic resonance-targeted biopsy.
Article in Urologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Current practice and perceptions of multiparametric magnetic resonance imaging and multiparametric ultrasound and prostatic biopsies for prostate cancer diagnosis in China: a nationwide survey.Quantitative imaging in medicine and surgery · 2025Article
- Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis.World journal of urology · 2023Article
- Utility of Magnetic Resonance Imaging for Localizing Prostate Cancer Near the Urethra in Men Who Are Candidates for Focal Gland Ablation.The Journal of urology · 2023Article
- Evaluation of the frequency of incidental findings and their clinical significance in multiparametric prostate magnetic resonance imaging examination.Polish journal of radiology · 2022Article
- Attitudes and experience of urology trainees in interpreting prostate magnetic resonance imaging.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.European urology focus · 2020Article
- Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey.Urologia internationalis · 2020Article
- Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.Urology · 2019Article
- Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer.Prostate cancer and prostatic diseases · 2019Article
- The current role of prostate multiparametric magnetic resonance imaging.Asian journal of urology · 2019Review
- MRI in active surveillance: a critical review.Prostate cancer and prostatic diseases · 2019Review
- Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer.Urologic oncology · 2019Article
- Incidental findings on multiparametric MRI performed for evaluation of prostate cancer.Abdominal radiology (New York) · 2018Article
- Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men.Prostate cancer and prostatic diseases · 2017Article
- The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.Current urology reports · 2017Review
- Magnetic resonance imaging detection of prostate cancer in men with previous negative prostate biopsy.Translational andrology and urology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
INTRODUCTION AND
objectiveMultiparametric magnetic resonance imaging (MRI) and magnetic resonance (MR) -targeted biopsy have a growing role in the screening and evaluation of prostate cancer. We aim to evaluate the current knowledge, attitude, and practice patterns of urologists regarding this new technique.
methodsAn anonymous online questionnaire was designed to collect information on urologists' beliefs and use of prostate multiparametric MRI and MR-targeted biopsy. The survey was sent to members of the Society of Urologic Oncology, the Endourological Society, and European Association of Urology. Multivariate logistic regression analysis was performed to determine predictors for use of prostate MRI and MR-targeted biopsy.
resultsA total of 302 responses were received (Endourological Society: 175, European Association of Urology: 23, and Society of Urologic Oncology: 104). Most respondents (83.6%) believe MR-targeted biopsy to be moderately to extremely beneficial in the evaluation of prostate cancer. Overall, 85.7% of responders use prostate MRI in their practice, and 63.0% use MR-targeted biopsy. The 2 most common settings for use of MR-targeted biopsy include patients with history of prior negative biopsy result (96.3%) and monitoring patients on active surveillance (72.5%). In those who do not use MR-targeted biopsy, the principal reasons were lack of necessary infrastructure (64.1%) and prohibitive costs (48.1%). On multivariate logistic regression analysis, practice in an academic setting (1.86 [1.02-3.40], P = 0.043) and performing greater than 25 radical prostatectomies per year (2.32 [1.18-4.56], P = 0.015) remained independent predictors for using MR-targeted biopsy.
conclusionsMost respondents of our survey look favorably on use of prostate MRI and MR-targeted biopsy in clinical practice. Over time, reduction in fixed costs and easier access to equipment may lead to further dissemination of this novel and potentially transformative technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.